Quality Investor

Progyny, Inc.

Rank #119Capital Return

PGNY · Nasdaq · Healthcare

Progyny, Inc. (PGNY) — Rank #119 by gross profitability (GP/assets 0.43) · ROE 12.9% · Piotroski F-Score 5 / 9.

As-of 2026-09-15 · CIK 0001551306 · all metrics point-in-time as of the filing date.

About

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States.

Show more

It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc.

was incorporated in 2008 and is headquartered in New York, New York.

Industry
Healthcare Plans
Sector
Healthcare
State
DE
Filer Category
Large accelerated filer
Fiscal Year End
December 31

Price History

PGNY-52.6% · -13.9% CAGRSPY+80.5% · +12.5% CAGR

Company Snapshot

P/E and reverse DCF are the primary valuation lenses at this stage.

Market Cap

$2.14B

P/E (annual)

42.8

P/S (annual)

1.7

P/B

4.7

P/OCF (annual)

10.2

Shareholder Yield

5.9%

Employees

835

Industry

Healthcare Plans

Exchange

Nasdaq

Signal Flags

3 green
Revenue growth acceleratingGrowth rate increasing year over year
Operating leverage expandingOperating income growing faster than revenue
Sequential beat (rev + EPS)Both revenue and EPS exceeded prior quarter — 2-quarter streak

Quality Profile

Profitability

1/1 pass
GP / assets
0.43
Return on equity
12.9%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
0.58
Current ratio
2.14×
Net cash
$236.93M

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
10.2%

Growth

2/2 pass
Revenue growth
10.4%
Piotroski F-Score
5 / 9
Share dilution
-5.9%

Terry Smith quality gate

Passes 1/5 Terry Smith thresholds

1 of 5 threshold not computable from filed data.

What Growth Is Priced In

Implied revenue growth (10Y)

1.9%

incredible deal

The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).

Buyback tailwind: -5.9% — per-share value needs a total required return of -4.0% once share-count change is priced in.

vs. own 6-year median revenue growth: 47.8%

within its own history

Cost-of-equity sensitivity (implied growth at different discount rates)

r = 8%

-2.1%

r = 10% (base)

1.9%

r = 12%

5.3%

Net debt / market cap: -9.5%

Base FCF: $191.8M3Y mean FCF: $183.6M

Valuation History

Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.

P / E

Price / diluted EPS

27.2xCheap
27.2xmed 58.4x127.4x

P / S

Price / revenue per share

1.2xCheap
1.2xmed 4.1x11.0x

P / B

Price / book value per share

3.1xCheap
3.1xmed 8.4x22.7x

P / GP

Price / gross profit per share

5.2xCheap
5.2xmed 19.1x54.1x

P / FCF

Price / free cash flow per share

8.3xCheap
8.3xmed 34.7x160.5x

FCF yield, shareholder yield, and buyback activity are the primary reads at this stage.

Profitability

Gross profitability (GP / assets)

0.43

Primary signal (Novy-Marx).

5th of 8 SIC 80 peers

Return on equity

12.9%

Gross margin

23.6%

7th of 8 SIC 80 peers

Revenue growth (YoY)

10.4%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

17.9%

Revenue CAGR (5Y)

30.2%

Earnings CAGR (3Y)

24.5%

FCF CAGR (3Y)

35.5%

Anti-fragile safety

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

0.58

3rd of 7 SIC 80 peers (best = lowest)

Current ratio

2.14×

5th of 8 SIC 80 peers

Quick ratio

2.06×

Net cash

$236.93M

Cash & equivalents minus total debt.

Cash-flow health

Free cash flow

$191.78M

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF / net income

2.28

Cash-backing of earnings.

FCF/NI divergence

Unfavorable divergence (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

10.2%

Stock-based comp intensity.

Piotroski F-Score

F-Score

5 / 9

Fundamental-strength score (0-9).

Lifecycle Phase History

20202025
Hypergrowth
Capital Return